Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by α-lactalbumin promoter

Molecular Cancer Therapeutics

Volumn 4, Issue 12, 2005, Pages 1850-1859

  Li, Xiong ^a   Zhang, Jie ^a   Gao, Huanling ^a   Vieth, Edyta ^a   Bae, Kyung Hee ^a   Zhang, Yan Ping ^a   Lee, Sang Jin ^a   Raikwar, Sudhanshu ^a   Gardner, Thomas A ^a   Hutchins, Gary D ^a   VanderPutten, Dale ^b   Kao, Chinghai ^a   Jeng, Meei Huey ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b 2661 Riva Road   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA LACTALBUMIN; E1A PROTEIN; E1B PROTEIN; LUCIFERASE; VIRUS DNA; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; ENZYME ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MICROBIAL ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS REPLICATION; WILD TYPE;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ADENOVIRUS E1B PROTEINS; ANIMALS; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; LACTALBUMIN; MALE; MAMMARY GLANDS, HUMAN; MICE; MICE, NUDE; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRULENCE; VIRUS REPLICATION;

EID: 30344484864     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0167     Document Type: Article

References (47)

1. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer - epidemiology, risk factors, and genetics. BMJ 2000;321:624-8.
2. Breast cancer facts and figures 2003-2004. Atlanta: American Cancer Society, Inc., 2003.
3. Aapro MS. Adjuvant therapy of primary breast cancer: a review of key findings from the 7th International Conference, St. Gallen, February 2001. Oncologist 2001;6:376-85.
4. Nathanson KL, Wooster R, Weber BL. Breast cancer genetics: what we know and what we need. Nat Med 2001;7:552-6.
5. Obermiller PS, Tait DL, Holt JT. Gene therapy for carcinoma of the breast: therapeutic genetic correction strategies. Breast Cancer Res 2000; 2:28-31.
6. Curiel DT. Gene therapy for carcinoma of the breast: genetic ablation strategies. Breast Cancer Res 2000;2:45-9.
7. Vassaux G, Lemoine NR. Gene therapy for carcinoma of the breast: genetic toxins. Breast Cancer Res 2000;2:22-7.
8. Strong TV. Gene therapy for carcinoma of the breast: genetic immunotherapy. Breast Cancer Res 2000;2:15-21.
9. Gomez-Navarro J, Arafat W, Xiang J. Gene therapy for carcinoma of the breast: pro-apoptotic gene therapy. Breast Cancer Res 2000;2:32-44.
10. Hart IR. Tissue specific promoters in targeting systemically delivered gene therapy. Semin Oncol 1996;23:154-8.
11. Bauerschmitz GJ, Barker SD, Hemminki A. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents [review]. Int J Oncol 2002;21:1161-74.
12. Curiel DT. Strategies to adapt adenoviral vectors for targeted delivery. Ann N Y Acad Sci 1999;886:158-71.
13. Stevenson SC, Rollence M, Marshall-Neff J, McClelland A. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol 1997;71:4782-90.
14. Haisma HJ, Grill J, Curiel DT, et al. Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Ther 2000;7:901-4.
15. Hsieh CL, Yang L, Miao L, et al. A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors. Cancer Res 2002;62:3084-92.
16. Anderson LM, Swaminathan S, Zackon I, et al. Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer. Gene Ther 1999;6:854-64.
17. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004;83: 249-89.
18. Chen L, Chen D, Manome Y, et al. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest 1995;96:2775-82.
19. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000;106:763-71.
20. Pandha HS, Martin LA, Rigg A, et al. Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 1999;17:2180-9.
21. Ring CJ, Blouin P, Martin LA, Hurst HC, Lemoine NR. Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumour-selective expression of a prodrug activating enzyme. Gene Ther 1997;4:1045-52.
22. Cohen C, Sharkey FE, Shulman G, Uthman EO, Budgeon LR. Tumor-associated antigens in breast carcinomas. Prognostic significance. Cancer 1987;60:1294-8.
23. Lee AK, DeLellis RA, Rosen PP, et al. α-Lactalbumin as an immunohistochemical marker for metastatic breast carcinomas. Am J Surg Pathol 1984;8:93-100.
24. Simickova M, Lang BA, Rejthar A, et al. Immunohistochemical localization of α-lactalbumin in human breast cancer tissue. Neoplasm 1989;36:11-20.
25. de Almeida PC, Pestana CB. Immunohistochemical markers in the identification of metastatic breast cancer. Breast Cancer Res Treat 1992; 21:201-10.
26. Thean ET, Toh BH. Serum human α-lactalbumin as a marker for breast cancer. Br J Cancer 1990;61:773-5.
27. Walker RA. The demonstration of α lactalbumin in human breast carcinomas. J Pathol 1979;129:37-42.
28. Vilotte JL, Soulier S. Isolation and characterization of the mouse α-lactalbumin-encoding gene: interspecies comparison, tissue- and stage-specific expression. Gene 1992;119:287-92.
29. Hakansson A, Zhivotovsky B, Orrenius S, Sabharwal H, Svanborg C. Apoptosis induced by a human milk protein. Proc Natl Acad Sci U S A 1995;92:8064-8.
30. Quirk SJ, Gannell JE, Funder JW. α-Lactalbumin production by rat mammary gland: prepartum emergence of resistance to glucocorticoids and progestins. Mol Cell Endocrinol 1988;58:183-9.
31. Maschio A, Brickell PM, Kioussis D, et al. Transgenic mice carrying the guinea-pig α-lactalbumin gene transcribe milk protein genes in their sebaceous glands during lactation. Biochem J 1991; 275:459-67.
32. Stacey A, Schnieke A, McWhir J, et al. Use of double-replacement gene targeting to replace the murine α-lactalbumin gene with its human counterpart in embryonic stem cells and mice. Mol Cell Biol 1994;14: 1009-16.
33. Stacey A, Schnieke A, Kerr M, et al. Lactation is disrupted by α-lactalbumin deficiency and can be restored by human α-lactalbumin gene replacement in mice. Proc Natl Acad Sci U S A 1995;92:2835-9.
34. Anderson LM, Krotz S, Weitzman SA, Thimmapaya B. Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach. Cancer Gene Ther 2000;7: 845-52.
35. Hallenbeck PL, Chang YN, Hay C, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999;10:1721-33.
36. Kurihara H, Zama A, Tamura M, et al. Glioma/glioblastoma-specific adenoviral gene expression using the nestin gene regulator. Gene Ther 2000;7:686-93.
37. Rodriguez R, Schuur ER, Lim HY, et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997;57: 2559-63.
38. Hitt MM, Graham FL. Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication. Virology 1990;179:667-78.
39. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999;59:4200-3.
40. Yu DC, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 1999;59:1498-504.
41. Li X, Zhang YP, Kim HS, et al. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer. Cancer Res 2005;65:1941-51.
42. Lee SJ, Kim HS, Yu R, et al. Novel prostate-specific promoter derived from PSA and PSMA enhancers. Mol Ther 2002;6:415-21.
43. Jeng MH, Kao C, Sivaraman L, et al. Reconstitution of estrogen-dependent transcriptional activation of an adenoviral target gene in select regions of the rat mammary gland. Endocrinology 1998;139:2916-25.
44. Hernandez-Alcoceba R, Pihalja M, Nunez G, Clarke MF. Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells. Cancer Gene Ther 2001;8:298-307.
45. Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther 2002;13:1737-50.
46. Tollefson AE, Ryerse JS, Scaria A, Hermiston TW, Wold WS. The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with ADP mutants. Virology 1996; 220:152-62.
47. Tollefson AE, Scaria A, Hermiston TW, et al. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 1996;70: 2296-306.